ArticleHealth science reports2026
Racial Disparities in Time to Treatment of Pancreatic Adenocarcinoma During the COVID-19 Era: A Retrospective Database Analysis.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The COVID-19 pandemic led to delayed treatment for pancreatic ductal adenocarcinoma (PDAC) and other cancers due to factors such as lockdown protocols, social distancing practices, and prioritization of emergency procedures. Demographic factors create disparities in pancreatic cancer care access, further impacting time to treatment. Prolonged time to treatment initiation has been associated with worse health outcomes for patients with solid tumor malignancies, particularly PDAC. Communities at higher risk of PDAC were disproportionately affected by the pandemic due to factors including residence in healthcare deserts, inadequate insurance, and low health literacy. This study aims to investigate whether racial disparities in time to treatment for PDAC were exacerbated during the COVID-19 pandemic, with particular attention to vulnerable populations. Methods: National Cancer Database (NCDB) data were utilized to identify patients diagnosed with PDAC between 2018 and 2020. Patients were categorized as either "pre-COVID" (2018) or "post-COVID" (2020). A two-way ANOVA and post hoc testing were conducted with time to treatment as the primary dependent variable. Results: A statistically significant relationship was identified between race and time to treatment ( Conclusion: The analysis revealed significant relationships between race, time of diagnosis, and time to treatment, with Chinese patients experiencing the most substantial increase in treatment delay during the pandemic. These findings demonstrate how COVID-19 disruptions intensified preexisting healthcare inequities and highlight the need to address demographic disparities in healthcare access.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.